Ted McCluskey, MD/PhD was the 2011 President of Sand Hill Angels and has been on their Board of Directors for the past 5 years. In addition, he is currently a Clinical Consultant for Biotech, Diagnostic and Medical Device companies. At Stanford, he is an advisor in the SPARK drug development program and to the medical device Program in Biodesign. At BayBio he has helped with the entrepreneur pitching programs, helped in planning medical device events and is a BayBio Medical Expert.
Prior to consulting, Ted was Chief Medical Officer and Vice President of Clinical at a Stanford cardiovascular diagnostic startup – Aviir – for three years. Prior to that, he oversaw cardiovascular clinical development at Scios (a Johnson&Johnson Company) where he was responsible for their lead product Natrecor and for VEGF-121. Prior to Scios, Ted was at Genentech for 8 years, overseeing clinical research on cardiovascular applications for TNKase,Bosentan, CathFlo Activase and for the anti-angiogenicophthalmic agent Lucentis. He led the clinical development for the cardiovascular application of VEGF-165 (vascular endothelial growth factor) by direct intra-coronary injection and has had extensive experience in both in-licensing and out-licensing projects. While at Genentech, he received additional training in Finance, Marketing and Management (Berkeley) and in Leadership and Strategy at an executive program at Harvard Business School.
Ted was trained as an interventional cardiologist (Cleveland Clinic) and was on the faculty of the University of Cincinnati for several years. Molecular biology and clinical cardiology training were at UCSF. His medicine residency was at Washington University in St. Louis as were his MD and PhD (Pharmacology). His undergraduate degree was in chemistry (with research honors) from Stanford.